Evidence for Myoinositol in PCOS
The evidence for myoinositol in PCOS is limited and inconclusive, with potential benefits for some metabolic parameters and insulin resistance, but insufficient data to support routine use for improving live birth rates or other critical reproductive outcomes 1.
Current Evidence Quality and Limitations
The 2024 systematic review informing the International Evidence-based PCOS Guidelines found that while myoinositol may improve certain metabolic measures, the overall evidence remains weak 1. The most significant limitation is that clinicians and patients must recognize the uncertainty of this evidence when making treatment decisions.
Metabolic and Hormonal Effects
Myoinositol demonstrates some benefits for:
- Insulin resistance: May improve HOMA-IR index (reduction of -0.65,95% CI -1.02 to -0.28) 2, with one 2024 prospective study showing reduction from 4.52 to 2.74 3
- Hormonal parameters: Decreases LH levels and LH/FSH ratio 3, increases estradiol levels (WMD 16.16,95% CI 2.01-30.31) 2
- Menstrual regularity: Approximately 68% of patients restored regular cycles in one study 3
However, no conclusive effect on testosterone levels has been demonstrated 2.
Reproductive Outcomes - The Critical Gap
Live Birth and Pregnancy
We are uncertain whether myoinositol improves live birth rates in subfertile women with PCOS undergoing IVF (OR 2.42,95% CI 0.75-7.83; very low-quality evidence) 4. Most critically, a 2025 randomized clinical trial of 464 pregnant women with PCOS found that myoinositol supplementation did not reduce the composite outcome of gestational diabetes, preeclampsia, or preterm birth (25.0% vs 26.8%, RR 0.93,95% CI 0.68-1.28) 5.
Miscarriage and Clinical Pregnancy
The evidence on miscarriage is contradictory and unreliable due to high heterogeneity driven by one study with an unusually high control group miscarriage rate 4. For clinical pregnancy rates, the evidence is very uncertain (OR 1.27,95% CI 0.87-1.85) 4.
Comparison with Standard Treatments
Metformin may be superior to myoinositol for waist-hip ratio and hirsutism, though reproductive outcomes show no clear difference 1. The primary advantage of myoinositol is fewer gastrointestinal adverse events compared to metformin 1, though metformin's side effects are typically mild and self-limited.
Formulation Considerations
Recent evidence suggests that combination therapy with myo-inositol/D-chiro-inositol at ratios of 40:1 to 100:1 may be more effective than either alone 6, 7. D-chiro-inositol alone is not recommended due to insufficient evidence and potential exacerbation of androgen synthesis 7. The addition of α-lactalbumin may improve absorption 7.
Clinical Bottom Line
Given the very low quality of evidence for meaningful clinical outcomes (live birth, pregnancy complications) and the 2025 negative trial for pregnancy outcomes 5, myoinositol cannot be routinely recommended as a primary therapy for PCOS. It may be considered as an adjunctive option for women with documented insulin resistance who cannot tolerate metformin, with the understanding that benefits are uncertain and primarily limited to metabolic parameters rather than reproductive outcomes. Shared decision-making is essential, emphasizing that this is not a proven fertility treatment despite widespread marketing claims.
Common Pitfalls to Avoid
- Do not prescribe myoinositol expecting improved live birth rates - the evidence does not support this
- Do not use D-chiro-inositol alone - it may worsen androgen excess
- Do not substitute myoinositol for proven therapies like lifestyle modification or metformin in appropriate candidates
- Do not recommend it for preventing pregnancy complications in women with PCOS - the 2025 RCT showed no benefit 5